Paying for MASH Medications, Scans & Care: Co-Pay Grants & Insurance Rights
New MASH therapies don't help anyone if sticker shock leaves them sitting at the pharmacy counter. Use these nonprofit co-pay foundations, manufacturer programs, and Medicare Part D protections.
Years ago, when we first put up a financial assistance page, charitable co-pay funds mostly covered Hepatitis C and brushed metabolic liver patients aside. Thankfully, assistance options look very different in 2026 — though pharmacy benefit managers still throw frustrating 'prior authorization' and 'step therapy' roadblocks in front of Rezdiffra, GLP-1s, and specialty scans.
Rule #1 when an insurance rejection letter lands in your mailbox: do not accept the first 'No' as final. Treat an initial denial as an incomplete-paperwork flag — when your doctor's office appeals with exact ICD-10 fibrosis codes and your FibroScan kPa or ELF report proving F2–F3 at-risk MASH, a large share of denials get overturned.
4 Steps When Insurance Denies a MASH Prescription
- 1. Check the exact ICD-10 & stage documentation: Make sure the claim specifies MASH (K75.81) + moderate-to-advanced hepatic fibrosis (K74.02, F2–F3) rather than unspecified fatty liver or weight loss.
- 2. Attach noninvasive staging proof: Include your actual VCTE/FibroScan kPa, ELF score, MRE, or FAST/MAST lab/imaging report.
- 3. Request a specialty peer-to-peer review: Ask your hepatologist or endocrinologist to speak to a GI/hepatology reviewer, not a general claims clerk.
- 4. File an external independent appeal: Under federal and state law, an outside independent medical reviewer can legally override your insurer's denial.
Lowering Out-of-Pocket Lab & Scan Bills
- FIB-4 is $0 extra: Calculated directly from the routine CBC (platelets) and CMP (AST/ALT) panels you already get at annual physicals.
- Compare hospital vs. freestanding imaging rates: Outpatient radiology centers and in-office FibroScan/Velacur exams avoid steep hospital facility fees that inflate bills 3x to 5x.
Independent Nonprofit Co-Pay, Insurance & Navigation Organizations
Conquering Prior Authorization (PA) & Step-Therapy Denials: Your Appeal Checklist
National health survey studies show that more than 1 in 3 U.S. adults with chronic liver disease experience medical bill hardship, and pharmacy benefit managers (PBMs) routinely flag specialty MASH prescriptions for automated prior-authorization (PA) rejection on the first pass. Why? Because automated claims software rejects files that omit a specific fibrosis code, confuses FDA-approved F2–F3 MASH treatment with excluded "cosmetic weight loss," or demands an outdated surgical liver biopsy that AASLD guidelines explicitly say you don't need.
When a denial letter arrives, request the insurer's exact Clinical Coverage Policy PDF for resmetirom or semaglutide (every plan must send it free on request) and make sure your doctor's specialty pharmacy coordinator includes all five items below in the appeal packet:
| Appeal Packet Item | Exact Codes & Clinical Proof Insurers Look For |
|---|---|
| 1. Dual ICD-10-CM Coding (MASH + Fibrosis Stage) | Pair K75.81 (MASH — listed in legacy ICD-10 billing tables under historical nonalcoholic steatohepatitis wording) together with a specific hepatic fibrosis code such as K74.02 (moderate-to-advanced F2–F3 fibrosis). Submitting generic fatty liver (K76.0) or obesity (E66.9) alone triggers instant automated rejection. |
| 2. Attached Noninvasive Staging Report (Not Just a Note) | Attach the actual lab/imaging PDF showing at-risk F2–F3 MASH: e.g., FibroScan VCTE LSM ~8.0–15.0 kPa, ELF score ~9.2–10.5, MRE ~3.1–4.4 kPa, or FAST ≥0.67, alongside recent FIB-4 and platelet counts (≥140,000–150,000/μL) — see Therapy Eligibility Thresholds. |
| 3. Explicit Confirmation of Non-Cirrhotic & Secondary Rule-Outs | A two-sentence clinician attestation confirming: (a) no cirrhosis or hepatic decompensation (no ascites, varices, encephalopathy, or jaundice), (b) alcohol intake below MetALD/ALD thresholds, and (c) viral hepatitis B/C and autoimmune liver disease excluded. |
| 4. Documented Nutrition, Movement & Step-Therapy Context | Chart documentation that the medication is prescribed alongside ongoing Mediterranean nutrition and physical activity — plus, if the PBM demands "step therapy" with off-label generics first, clear medical rationale why pioglitazone or high-dose vitamin E is clinically inadequate or contraindicated for your heart, bone, or fibrosis profile. |
| 5. AASLD Biopsy-Free Citation + Specialty Peer-to-Peer | Cite the AASLD Practice Guidance Update stating liver biopsy is unnecessary in routine clinical MASH care; request a GI/hepatology specialty peer-to-peer review; and if denied internally, file a state/federal External Independent Medical Review (overturns a substantial share of improper denials). |
Medicare Part D's ~$2,000–$2,100 Out-of-Pocket Cap & Monthly "Smoothing"
If you're on Medicare like me, the rules around expensive specialty medications changed dramatically starting in 2025. Previously, Medicare Part D's 5% "catastrophic coinsurance" had no hard ceiling — a $48,000/year specialty prescription could easily drain $3,500 to $6,000+ out of a retiree's savings every single year, and federal anti-kickback statutes prohibit Medicare beneficiaries from using commercial $0 drug-company co-pay cards. Under current federal law, total annual out-of-pocket spending across all covered Part D prescriptions combined hits a hard ceiling ($2,000 in 2025, indexed to $2,100 in 2026) — after which your co-pays drop to $0 through December 31.
Medicare Prescription Payment Plan ("Smoothing")
- Fixes January sticker shock: Without smoothing, filling a high-cost MASH drug in January can trigger the entire ~$2,100 annual cap on Refill #1.
- $0-interest monthly cap: Every Part D and Medicare Advantage drug plan must let you opt in (by phone or online, free, with zero interest or fees) to spread your out-of-pocket cap into manageable monthly bills across the rest of the calendar year.
- Important catch: The ~$2,100 cap only applies once your Part D plan approves coverage (either on-formulary or via a prescriber Formulary Exception for F2–F3 MASH).
Commercial Co-Pay Accumulator Traps & Hospital Scan Fees
- Watch out for "Co-Pay Accumulators": On commercial employer plans, manufacturer co-pay cards often bring your pharmacy bill to $0–$25/month — but some PBMs refuse to count manufacturer assistance toward your deductible, causing a surprise bill mid-year if the card hits an annual dollar cap. Ask your specialty pharmacy whether a direct patient-reimbursement option avoids accumulator tracking (20+ states also restrict accumulators on state-regulated plans).
- Beat $2,500 hospital imaging facility fees: Hospital outpatient radiology departments routinely tack steep facility markups onto FibroScan (
CPT 91200), ultrasound elastography (CPT 76981), or MR elastography (CPT 76391) — see Ordering & CPT Codes. Always ask for an in-office clinic elastography scan or a freestanding outpatient imaging center quote (and your federal Good Faith Estimate if self-paying).
Additional Manufacturer & Foundation Programs to Check in 2026
| Program / Foundation | Who Qualifies | What to Ask Your Specialty Pharmacy or Doctor |
|---|---|---|
| Madrigal Patient Support (Rezdiffra) | Commercially insured ($0 or low co-pay savings card) and uninsured/underinsured Patient Assistance Program (PAP) pathways. | Ask your hepatologist's prior-authorization coordinator to enroll you in Madrigal Patient Support simultaneously with your FibroScan/ELF submission; bridge supply programs may assist during prolonged PA reviews. |
| NovoCare (Wegovy / Ozempic) & Lilly Cares | Commercial co-pay savings cards, transparent direct-to-patient cash pharmacy tiers, and income-based uninsured PAPs. | Ensure your prescriber submits Wegovy under its FDA F2–F3 MASH indication (ICD-10 K75.81 + fibrosis proof) rather than weight management, as many medical/pharmacy plans cover MASH even when excluding cosmetic weight loss. |
| PAN Foundation & The Assistance Fund (TAF) | Medicare Part D & insured patients facing specialty coinsurance (typically household income ≤400%–500% of Federal Poverty Level). | Disease funds open and close dynamically as donations arrive — sign up for free automated email/text alerts on PAN Foundation's FundFinder tool so you can apply the same hour a liver fund reopens. |
| Patient Advocate Foundation (PAF) Case Management | Patients battling complex prior-authorization denials, step therapy, Medicare formulary exceptions, or workplace medical leave. | Free professional case managers help assemble clinical appeal packets (FIB-4, kPa stiffness, cardiometabolic history) when an insurer initially rejects a MASH therapy or specialty imaging claim. |
Common Questions Patients & Families Ask
Why can't I use a $0 drug-company co-pay card if I have Medicare Part D, Medicare Advantage, or Medicaid?
Under the federal Anti-Kickback Statute, pharmaceutical manufacturers are barred from offering commercial co-pay coupons on prescriptions paid partially by federal healthcare programs (Medicare, Medicaid, TRICARE). Instead, Medicare patients rely on three legal pathways: (1) the federal Medicare Part D ~$2,000–$2,100 annual out-of-pocket cap + $0-interest monthly smoothing, (2) Social Security's Extra Help (Low-Income Subsidy), and (3) independent 501(c)(3) charitable disease funds like HealthWell Foundation, PAN Foundation, and The Assistance Fund.
My employer plan rejected Wegovy saying 'weight-loss medications are excluded' — can I still appeal for MASH?
Often yes! Many employer plans exclude anti-obesity drugs when prescribed solely for weight loss (ICD-10 E66.9), yet cover specialty medical therapies for organ-threatening chronic diseases. Because Wegovy received a separate FDA accelerated approval for non-cirrhotic F2–F3 MASH in August 2025, ask your hepatologist or endocrinologist to submit a medical-necessity exception coded strictly under MASH with F2–F3 liver fibrosis (K75.81 + K74.02) with your FibroScan/ELF report attached.
What should I do when HealthWell or PAN Foundation says their MASH/liver grant fund is 'closed'?
Charitable co-pay funds open and close throughout the year as corporate and philanthropic donations arrive — sometimes staying open for only 48 hours at a time! Register free on PAN Foundation's FundFinder website (panfoundation.org), which monitors multiple major charitable foundations at once and sends an instant text or email alert the moment a liver/MASH fund reopens so you can apply immediately.
How do I avoid a surprise $2,000 hospital bill for an outpatient liver ultrasound or elastography scan?
Before scheduling, ask two plain questions: "Is this imaging site billed as a hospital outpatient department (with a facility fee) or an independent freestanding clinic?" and "What is my contracted cost for CPT 91200 (FibroScan) or CPT 76981 (ultrasound elastography)?" Whenever possible, choose an in-office hepatology FibroScan/Velacur or freestanding radiology clinic rather than a main hospital building.
Where to Go Deeper: Related Guides & Trusted Resources
Review clinical criteria, dosing, and drug-interaction checks for Rezdiffra, Wegovy, tirzepatide, and pioglitazone.
Exact CPT and LOINC billing codes for FIB-4 labs, ELF, FibroScan (91200), SWE (76981), MRI-PDFF, and MRE (76391) to verify insurer pricing upfront.
Exact noninvasive kPa and blood-panel numbers your physician's prior-authorization coordinator needs in your chart.
Official federal instructions on opting into $0-interest monthly cap smoothing across your Part D specialty prescriptions.
Check real-time grant status across charitable co-pay foundations and set instant email/SMS alerts when funds open.
Free non-commercial sample appeal letters, step-therapy exception guides, and external medical review trackers by state.



